

WE CLAIM:

1. A method of designing a humanized immunoglobulin (Ig) chain having one or more complementarity determining regions (CDR's) from a donor Ig and a framework region from a human Ig, said method comprising: comparing
5 the framework or variable region amino acid sequence of the donor Ig with corresponding sequences in a collection of human Ig chains; and selecting to provide the human Ig framework one of the about three most homologous sequences
10 from the collection.
2. A method according to Claim 1, wherein the human Ig sequence is selected from a collection of at least about ten to twenty Ig chain sequences.
15
3. A method according to Claim 1, wherein the human Ig chain sequence selected has the highest homology in the collection to the donor Ig sequence.
- 20 4. A method according to Claim 1, wherein the human Ig framework sequence selected is at least about 65% homologous to the donor Ig framework sequence.
- 25 5. A method according to Claim 1, wherein the immunoglobulin chain is a heavy chain.
6. A method according to Claim 1, wherein the humanized Ig chain comprises a human constant region.
- 30 7. An immunoglobulin comprising two light/heavy chain pairs, wherein at least one chain is designed in accordance with Claim 1.

8. A method of designing a humanized immunoglobulin chain having a framework region from a human acceptor immunoglobulin and complementarity determining regions (CDR's) from a donor immunoglobulin capable of binding to an antigen, said method comprising the steps of substituting at least one human framework amino acid of the acceptor immunoglobulin with a corresponding amino acid from the donor immunoglobulin at a position in the immunoglobulins where:

(a) the amino acid in the human framework region of the acceptor immunoglobulin is rare for said position and the corresponding amino acid in the donor immunoglobulin is common for said position in human immunoglobulin sequences; or

(b) the amino acid is immediately adjacent to one of the CDR's; or

(c) the amino acid is predicted to have a side chain atom within about 3Å of the CDR's in a three-dimensional immunoglobulin model and to be capable of interacting with the antigen or with the CDR's of the humanized immunoglobulin.

9. A method according to Claim 8, wherein the humanized immunoglobulin chain comprises in addition to the CDR's at least three amino acids from the donor immunoglobulin chosen by criteria (a), (b) or (c).

10. A method according to Claim 9, wherein at least one of the amino acids substituted from the donor is immediately adjacent a CDR.

11. A method according to Claim 9, wherein said humanized immunoglobulin chain is a heavy chain.

12. An immunoglobulin comprising two light/heavy chain pairs, wherein at least one chain is designed in accordance with Claim 8.

13. An immunoglobulin according to Claim 12, which is specifically reactive with an antigen at an affinity of at least about 10^8 M^{-1} or stronger.

5 14. An immunoglobulin according to Claim 12, wherein the designed chain is a light chain comprising about 214 amino acids.

10 15. An immunoglobulin according to Claim 12, wherein the designed chain is a heavy chain comprising about 446 amino acids.

15 16. A DNA sequence which upon expression encodes a humanized immunoglobulin chain according to Claim 1 or Claim 8.

17. A method for improving the affinity of a humanized immunoglobulin (Ig) to an antigen, by replacing amino acids of the human Ig framework with amino acids from the donor Ig framework at positions where:

20 (a) the amino acid in the human framework region of the first immunoglobulin is rare for said position and the corresponding amino acid in the donor immunoglobulin is common for said position in human immunoglobulin sequences; or

25 (b) the amino acid is immediately adjacent to one of the CDR's; or

30 (c) the amino acid is predicted to have a side chain atom within about 3Å of the CDR's in a three-dimensional immunoglobulin model and to be capable of interacting with the antigen or the CDR's of the humanized immunoglobulin.

35 18. A method according to Claim 17, wherein the additional amino acids comprise up to three amino acids, each of which is immediately adjacent to one of the CDR's in the second Ig.

19. A method according to Claim 17, wherein the additional amino acids comprise one amino acid immediately adjacent to a CDR.

5 20. A method according to Claim 17, wherein the additional amino acids comprise at least two amino acids from the donor Ig which are predicted by modelling to be capable of interacting with the antigen or the CDR's.

10 21. A method according to Claim 20, wherein said two or more amino acids are predicted to be within about 3Å of the donor Ig CDR's.

15 22. A method according to Claim 17, wherein the humanized Ig has an affinity to the antigen within about 2 to 3 fold of the donor Ig.

23. A method according to Claim 17, wherein the antigen is a protein.

20 24. A method of producing a humanized immunoglobulin containing a heavy chain and a light chain designed in accordance with Claim 17, said method comprising:
culturing a host capable of expressing said heavy
chain, said light chain, or both, under conditions suitable
25 for production of said chains; and
recovering from the culture said humanized
immunoglobulin.

30 25. A polynucleotide composition comprising a DNA sequence coding for a humanized immunoglobulin designed in accordance with Claim 17.

35 26. A method of producing an improved humanized immunoglobulin comprising expressing the polynucleotide composition of Claim 25.

27. A cell transformed with a polynucleotide composition according to Claim 25.

28. A composition comprising a humanized immunoglobulin secreted by a cell line according to Claim 24.

5

10

15

20

25

30

35